The fate of an experimental dementia drug will be decided within days. On Monday, the Food and Drug Administration is set to announce whether it will approve Biogen’s antibody-based therapy aducanumab as a treatment for Alzheimer’s disease—the first intended to slow down the progression of the incurable ailment. But…
from Gizmodo https://ift.tt/2T0PQUT
